BLIRT S.A.

Awarded as Most Innovative Company in 2014, with 10 Technologies Patented Worldwide or Unprecedented Milestones achieved, Canvax™ manafactures High Quality & Low Price products inside next categories: DNA Cloning, Mammalian & Bacterial Expression, Dual Reporters, GPCRs, Cell Lines, Viral Packing Systems, DNA & RNA Extraction kits, Cell Assays, PCR & qPCR Essentials, Food Science, Recombinant Proteins, Custom Solutions, R&D Services, and much more Innovative Solutions.

Currently, we are one of the fastest growing Life Science Companies thanks the commitment of our 26 employees with the Culture of Excellence through our advanced Manufacturing and Quality-control systems, in-depth market knowledge, best delivery rates, World-class technical Distributor Support, training, Breakthrough Promotions and R&D capabilities.

Cerbios is a swiss privately held company specialized in the development and manufacturing of chemical and biological APIs for its world-wide partners.

The exclusive R&D and manufacturing expertise is available to our Pharma partners needing to develop and scale-up NCE or NBE for clinical trials, registration and commercial purpose.

cGMP APIs made by Cerbios in its FDA inspected site in Switzerland are sold worldwide mainly to pharma companies including EU, USA and Japan.

Cerbios is specialized in Reduced Folates (world leader position) but also in the manufacturing of High Potency Active Ingredients (HPAPIs) with a series of Vitamin D derivatives requiring sophisticated production units with high containment levels.

Another core business is the research, development and production of Probiotics of Pharma quality.
On top of that, in the last 17 years, CERBIOS has acquired a vast experience with Recombinant Proteins from mammalian cells (CHO) based on a state-of-the-art platform.

Service for third parties in exclusive manufacturing is concentrated in the area of HPAPI and Recombinant Proteins.

Full CMC support is given to our customers in order to provide them with the supply of cGMP clinical batches, registration/validation material and commercial manufacturing. Paramount to that is the supply of all documentation required for a successful registration.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry.
Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing.
Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

Who are we?
Efarmes is a generic pharmaceutical company devoted to develop and manufacture generics for third parties all over the world. Efarmes Generics Company is part of Lacer Group. Our head offices, manufacturing site with EU cGMP’s and R&D area are in Barcelona.

What we do?
Efarmes Generics Company seeks partners that want to in-license and market the generics. Our partners are both multinational and local pharmaceutical companies on the five continents. Efarmes Generics Company offers tailored-made proposals such as full development and manufacturing of generic pharmaceutical products ready to be marketed by third parties under their own brand name, co-development of generic products, and contract manufacturing.

How we do it?
Efarmes Generics Company covers all levels from formulation to finished product delivery. Efarmes Generics Company currently supplies finished dosage forms to many key players all over the world. Our manufacturing site plant produced last year 24 M units (3.240 batches) with 99,9% Quality Control Conforming.

Our Business Proposal
Our main business model is the out license and supply of generic finished dosage forms. Our dossiers are in EU CTD format and ready to file. We have some MAs available in Europe.

Dossiers ready to file:
- Rasagiline (Parkinson’s diseases)
- Alprazolam (Anxiolytic)
- Deflazacort (Corticosteroid)
- Modafinil (Narcolepsy)
- Sildenafil (Erectil Dysfunction)
- Pioglitazone (Diabetes)
- Rivastigmine (Alzheimer diseases)

Dossiers under development:
- Olmersartan + Amlodipine + Hidroclorothiazide (Hypertension). Q2 2016 Bioequivalence studies on-going.
- Tapentadol, retard tabs, (Neurophatic Pain). Dossier will be available in 2018.

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries prior to the expiry date of valid patents are possible.

Please, contact us on generics@efarmes.es

Since December 2014, the new Reig Jofre is the pharma company resulting from the merger between Laboratorio Reig Jofre SA and the publicly traded company Natraceutical SA, which resulted in the fifth Spanish pharma company listed on the stock exchange (ticker: RJF).

Reig Jofre directs its activity to the research, development, manufacturing and marketing of medicines and food supplements, as well as to the specialized manufacturing for third-parties. The company focuses its R&D on the development of new indications and/or dosage forms of known active principles, generics with special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and nutritional supplements, as well as on the development of innovative molecules in partnership with start-ups and research centers.

For further information, visit our website.